All In Biotech

Drug Trial Radar · NCT05836987

The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

REACT-AF: Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 5,350 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

5,350

Planned (sponsor's estimate)

Start

Jul 13, 2023

Primary completion

Jul 31, 2029

Study completion Jul 31, 2029

Sponsor

Lead sponsor
Johns Hopkins UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI); Northwestern University
First posted
May 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 22 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

REACT-AF is a multicenter prospective, randomized, open-label, blinded endpoint (PROBE design), controlled trial comparing the current Standard Of Care (SOC) of continuous Direct Oral Anticoagulation (DOAC) use versus time-delimited (1 month) DOAC guided by an AF-sensing Smart Watch (AFSW) in participants with a history of paroxysmal or persistent Atrial Fibrillation (AF) and low-to-moderate stroke risk.

Conditions

  • Atrial Fibrillation

Interventions

  • AFSW Guided DOACDevice

    The AFSW will intermittently and passively assess for rhythm irregularities consistent with AF and notify the wearer and coordinating center if a threshold AF event has occurred.

  • Continuous DOAC therapyDrug

    DOACs will be prescribed to patients according to the treating healthcare provider(s) according to labeling instructions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To assess whether AFSW-guided, time-delimited DOAC therapy is non-inferior to continuous DOAC therapy for a composite endpoint that includes: (1) Ischemic stroke; (2) Systemic embolism; (3) All-cause mortality.Time frame: At 60 months

Locations

93 sites in 1 country. Site status is shown where the registry gives one.

  • Banner University

    Phoenix, Arizona · Recruiting

  • University of Southern California - Keck School of Medicine

    Los Angeles, California · Recruiting

  • University of California Los Angeles (UCLA Health)

    Los Angeles, California · Recruiting

  • UC Davis Health

    Sacramento, California · Recruiting

  • Scripps Health

    San Diego, California · Recruiting

  • Kaiser Permanente

    San Francisco, California · Not yet recruiting

  • Stanford University

    Stanford, California · Recruiting

  • University of Colorado

    Aurora, Colorado · Recruiting

  • South Denver Cardiology Associates, P.C.

    Littleton, Colorado · Recruiting

  • Medical Faculty Associates George Washington University

    Washington D.C., District of Columbia · Withdrawn

  • BayCare Health Systems

    Clearwater, Florida · Recruiting

  • University of Florida

    Gainesville, Florida · Recruiting

  • Mayo Clinic

    Jacksonville, Florida · Recruiting

  • University of Miami - Leonard S. Miller SOM

    Miami, Florida · Recruiting

  • Sarasota Memorial Health Care System

    Sarasota, Florida · Active not recruiting

  • Cleveland Clinic Florida

    Stuart, Florida · Withdrawn

  • Baycare Health Systems Clearwater

    Winter Haven, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Georgia Arrhythmia Consultants and Research Institute

    Warner Robins, Georgia · Recruiting

  • University of Illinois Chicago

    Chicago, Illinois · Recruiting

  • Northwestern University

    Chicago, Illinois · Recruiting

  • Rush University Medical Center

    Chicago, Illinois · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • Loyola University Chicago

    Chicago, Illinois · Recruiting

  • Alexian Brothers Health System

    Elk Grove Village, Illinois · Recruiting

  • NorthShore University HealthSystem

    Evanston, Illinois · Recruiting

  • Midwest Cardiovascular Institute

    Naperville, Illinois · Recruiting

  • Ascension St. Vincent

    Indianapolis, Indiana · Recruiting

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa · Recruiting

  • Maine Medical Partners MaineHealth Cardiology

    Scarborough, Maine · Recruiting

  • Johns Hopkins University

    Baltimore, Maryland · Recruiting

  • Tufts Medical Center

    Boston, Massachusetts · Recruiting

  • Mass General Hospital

    Boston, Massachusetts · Recruiting

  • Brigham and Women's Hospital

    Boston, Massachusetts · Recruiting

  • Boston Medical Center

    Boston, Massachusetts · Recruiting

  • BMC - Brighton

    Boston, Massachusetts · Recruiting

  • St. Elizabeth's Medical Center

    Boston, Massachusetts · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Lahey Hospital & Medical Center

    Burlington, Massachusetts · Recruiting

  • UMass Chan Medical School

    Worcester, Massachusetts · Active not recruiting

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.